TC3.6 is a PDE7 selective inhibitor (IC50 = 1.04 µM). In an Experimental Autoimmune Encephalomyelitis (EAE) murine model, TC3.6 reduced levels of IL-17, blocked infiltration of immune cells into the CNS and elevated levels of the Treg marker Foxp3. TC3.6 also enhances survival and differentiation of oligodendrocyte precursor cells.
Features and Benefits
This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.